Carisma Therapeutics (CARM) - 2024 FY - Earnings Call Presentation

Clinical Programs & Data - CT-0508 monotherapy showed stable disease (SD) in 29% (4/14) of patients, with 44% SD in HER2 3+ patients [13] - 75% (6/8) of HER2 3+ patients exhibited a decrease in ctDNA, with reductions up to 93% [17] - CT-0525, a CAR-Monocyte therapy, has a ~2,000-fold increased exposure compared to CT-0508 in preclinical models [44] - The first patient was treated with CT-0525 in 2Q 2024, with initial data expected in 4Q 2024 [43] In Vivo CAR-M Collaboration with Moderna - The collaboration includes up to 12 targets, with 7 nominated [64] - Carisma received an $80 million upfront payment and is eligible for over $3 billion in potential milestones and royalties [64] - Nomination of the first development candidate targeting GPC3 for HCC triggered a $2 million milestone payment [6, 65] Financial Status - As of June 30, 2024, Carisma had $40.4 million in cash and cash equivalents [100] - The company's cash runway is expected to last into 3Q 2025 [6, 100] Fibrosis Program - Preclinical data demonstrates that engineered macrophages can reduce liver fibrosis, with Relaxin-IL10 macrophages showing >100% reduction in collagen in one model [84] - Nomination of a development candidate for liver fibrosis is expected in 1Q 2025 [8, 93]